Studying tautomerism in an important pharmaceutical Glibenclamide (cas 10238-21-8) confined in the thin nanometric layers
-
Add time:07/23/2019 Source:sciencedirect.com
The uniform thin films with variable thicknesses (d = 49, 120, 220 nm) of active pharmaceutical ingredient (API) Glibenclamide (cas 10238-21-8) (GCM) was spin-coated and investigated using broadband dielectric, grazing incident FTIR spectroscopies, atomic force microscopy, and ellipsometry. Data analysis revealed that nanoconfined systems consist of a mixture of amide and imidic acid forms of this pharmaceutical, wherein the ratios of both tautomeric forms in the thin films were different with respect to the molten supercooled bulk system. Moreover, variation in the populations of glibenclamide tautomers, i.e. higher amide to imides ratio in the spatially restricted API with respect to the bulk sample, had a strong impact on the character of the proton transfer reaction. In this context, the kinetic curves constructed on the base of infrared data for the bulk system follow the sigmoidal shape, characteristic for the autocatalytic reaction, while results obtained for the confined samples provide exponential character and indicate Ist order transformation. This allows hypothesizing that the autocatalytic nature of the tautomerism in the bulk sample is most likely related to the formation of the amide tautomers which further catalyze the progress of imide-amide transformation. Our results are the first studies showing that the change in the thickness of the film may affect the properties and isomerization kinetics in a pharmaceutical systems. Finally, our data open a new perspective for developing new drug delivery systems.
We also recommend Trading Suppliers and Manufacturers of Glibenclamide (cas 10238-21-8). Pls Click Website Link as below: cas 10238-21-8 suppliers
Prev:Poly-3-hydroxyalkanoates from marine and freshwater cyanobacteria
Next:Electrochemical detection of gliclazide and Glibenclamide (cas 10238-21-8) on ZnIn2S4 nanoparticles-modified carbon ionic liquid electrode) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Characterization and evaluation of different mesoporous silica kinds as carriers for the development of effective oral dosage forms of Glibenclamide (cas 10238-21-8)07/31/2019
- Controlled release of Glibenclamide (cas 10238-21-8) from monolithic silica subdermal implants produced by the sol-gel process and its use for hyperglycaemia treatment in a murine model07/30/2019
- Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a Glibenclamide (cas 10238-21-8)-induced canine hypoglycaemia model07/29/2019
- Peceosomes for oral delivery of Glibenclamide (cas 10238-21-8): In vitro in situ correlation07/28/2019
- Low-voltage online stimulated microextraction of Glibenclamide (cas 10238-21-8) from whole blood07/27/2019
- Neuroprotective potential of Glibenclamide (cas 10238-21-8) is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage07/26/2019
- Role of AKR1C3 in renal injury and Glibenclamide (cas 10238-21-8) is anti-inflammatory in preeclamptic rats07/25/2019
- Electrochemical detection of gliclazide and Glibenclamide (cas 10238-21-8) on ZnIn2S4 nanoparticles-modified carbon ionic liquid electrode07/24/2019